New drug IRL757 tested in healthy seniors – no treatment yet
NCT ID NCT06699628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called IRL757 in 12 healthy volunteers aged 65 to 89. The goal was to see how the drug is processed in the body and check for any safety issues. No treatment for any disease was given; this is a first step to gather information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTC Clinical Trial Consultants AB
Uppsala, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain zaps could reignite motivation in stroke survivors
- Brain scans aim to unlock the mystery of Post-Stroke apathy
- Scientists use video and sensors to objectively measure apathy
- ADHD Drug's secret power: boosting motivation in healthy brains?
- Study links apathy to different fatigue types in seniors
- Music may reawaken motivation in Parkinson's patients